Imetelstat (GRN163L)--telomerase-based cancer therapy

Area of Science:

• Cell Biology
• Molecular Biology
• Oncology

Background:

• Telomeres and telomerase regulate human cell lifespan.
• Normal cells have limited divisions due to telomere shortening, unlike cancer cells which exhibit unlimited proliferation via high telomerase expression.
• Telomerase is a key target for cancer diagnostics and therapeutics due to its role in tumor growth.

Purpose of the Study:

• To detail the structure and mechanism of action of imetelstat.
• To review preclinical and clinical data for imetelstat.
• To discuss the future prospects of imetelstat in cancer therapy.

Main Methods:

• Structural analysis of imetelstat.
• Assessment of imetelstat's mechanism of action.
• Review of preclinical and clinical trial data.

Main Results:

• Imetelstat is a potent and specific inhibitor of telomerase.
• The drug has demonstrated efficacy in preclinical studies and is currently in clinical trials.
• Its mechanism involves blocking telomerase activity, thereby limiting cancer cell proliferation.

Conclusions:

• Imetelstat represents a novel therapeutic strategy targeting telomerase in cancer.
• The drug's unique mechanism and clinical progress position it as a promising cancer treatment.
• Further clinical evaluation is essential to establish imetelstat's full therapeutic potential.